ArticleThe American journal of pathology1998
Immunolocalization of putative human liver progenitor cells in livers from patients with end-stage primary biliary cirrhosis and sclerosing cholangitis using the monoclonal antibody OV-6.
Article in The American journal of pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 136 citations in OpenAlex.
- Sequence of events leading to primary biliary cholangitis.World journal of gastroenterology · 2023Review
- Update on Hepatobiliary Plasticity.Seminars in liver disease · 2023Article
- WNT7B Regulates Cholangiocyte Proliferation and Function During Murine Cholestasis.Hepatology communications · 2021Article
- Generation of Hepatobiliary Cell Lineages from Human Induced Pluripotent Stem Cells: Applications in Disease Modeling and Drug Screening.International journal of molecular sciences · 2021Review
- Targeted Apoptosis of Ductular Reactive Cells Reduces Hepatic Fibrosis in a Mouse Model of Cholestasis.Hepatology (Baltimore, Md.) · 2020Article
- If It Looks Like a Duct and Acts Like a Duct: On the Role of Reprogrammed Hepatocytes in Cholangiopathies.Gene expression · 2020Article
- Towards Bioengineered Liver Stem Cell Transplantation Studies in a Preclinical Dog Model for Inherited Copper Toxicosis.Bioengineering (Basel, Switzerland) · 2019Review
- Neonatal McCune-Albright Syndrome: A Unique Syndromic Profile With an Unfavorable Outcome.JBMR plus · 2019Article
- Understanding the marvels behind liver regeneration.Wiley interdisciplinary reviews. Developmental biology · 2019Review
- Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances.Hepatology (Baltimore, Md.) · 2019Review
- Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues for a Better Understanding of the "Reactive" Biliary Epithelial Phenotype.Stem cells international · 2016Review
- In vitro culture of isolated primary hepatocytes and stem cell-derived hepatocyte-like cells for liver regeneration.Protein & cell · 2015Review
- Isolation and Expansion of Hepatic Stem-like Cells from a Healthy Rat Liver and their Efficient Hepatic Differentiation of under Well-defined Vivo Hepatic like Microenvironment in a Multiwell Bioreactor.Journal of clinical and experimental hepatology · 2015Article
- Ethanol negatively regulates hepatic differentiation of hESC by inhibition of the MAPK/ERK signaling pathway in vitro.PloS one · 2014Article
- Stem cells in liver regeneration and their potential clinical applications.Stem cell reviews and reports · 2013Review
- Vascular endothelial growth factors in progenitor cells mediated liver repair.Hepatobiliary surgery and nutrition · 2013Article
- Development of the bile ducts: essentials for the clinical hepatologist.Journal of hepatology · 2012Review
- Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration.The Journal of clinical investigation · 2011Article
- Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis.Hepatology (Baltimore, Md.) · 2011Article
- Liver regeneration: alternative epithelial pathways.The international journal of biochemistry & cell biology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term oval cell describes small cells with oval nuclei that arise in the periphery of the portal tracts in rat models of hepatocarcinogenesis and injury and can differentiate into either hepatocytes or bile duct cells, ie, are bipotential. The presence of such cells in human liver is controversial. Here, immunolocalization of OV-6 and two biliary markers, cytokeratin 19 (CK-19) and human epithelial antigen 125 (HEA-125) is compared in normal adult human livers and in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) liver sections. CK-19 and HEA-125 stained bile ducts and ductules in normal liver as well as proliferating ductular structures in diseased livers. OV-6 did not label ducts or ductules in normal liver, but in PBC and PSC stained numerous proliferating ductular and periductular cells and lobular hepatocytes. In PBC, discrete OV-6-positive cells with a mature biliary-cell-like morphology were seen integrated into some intact bile ducts as well as occasional small immature oval-like cells. In addition, in PSC, hepatocytes in regenerating lobules were also strongly stained with OV-6, and on close inspection, in both PBC and PSC, oval cells and small hepatocytes at the margins of the lobules were strongly labeled. In contrast to the rat liver, OV-6 and CK-19 staining did not always co-localize. It is proposed that the small OV-6-positive oval cells are analogous to those seen in rat models and may represent human liver progenitor cells that may differentiate into OV-6-positive ductal cells or lobular hepatocytes.
Indexed as
Identifiers
9502419PMC1858380W24550614What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.